Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.61 |
| ▸ | CTSK | P43235 | 8/20 | 0.61 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498132 | 1.00 | REN (0.61) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL24345963 | 0.96 | BIRC2 (0.62) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL22962429 | 0.96 | REN (0.61) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL22962240 | 0.93 | BIRC2 (0.60) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL29651542 | 0.91 | REN (0.57) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL12890828 | 0.90 | KLK5 (0.58) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL8145513 | 0.90 | CTSK (0.56) | RENCTSKBIRC2KLK5CTSS | |
| SCHEMBL20030598 | 0.90 | CTSS (0.68) | RENCTSKKLK5CTSSCTSL | |
| SCHEMBL30135036 | 0.90 | CTSS (0.68) | RENCTSKKLK5CTSSCTSL | |
| SCHEMBL17138017 | 0.90 | CTSS (0.68) | RENCTSKKLK5CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | REN 848/4885CTSK 1235/4885BIRC2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.